A retrospective trial to evaluate the role of 99mTc-sestamibi (MIBI) brain single-photon emission tomography (SPET) in patients with glioblastoma multiforme after chemotherapy with Carmustine-polifeprosan-20-wafer

Trial Profile

A retrospective trial to evaluate the role of 99mTc-sestamibi (MIBI) brain single-photon emission tomography (SPET) in patients with glioblastoma multiforme after chemotherapy with Carmustine-polifeprosan-20-wafer

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2015

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top